146 related articles for article (PubMed ID: 11235536)
1. Evaluation and comparison between the effects on intraocular pressure and retinal blood flow of two antiglaucomatous drugs administered in monotherapy: brimonidine and latanoprost. Preliminary results.
Rolle T; Cipullo D; Vizzeri GM; Triggiani A; Brogliatti B
Acta Ophthalmol Scand Suppl; 2000; (232):50-2. PubMed ID: 11235536
[No Abstract] [Full Text] [Related]
2. Changes in intraocular pressure and ocular perfusion pressure after latanoprost 0.005% or brimonidine tartrate 0.2% in normal-tension glaucoma patients.
Liu CJ; Ko YC; Cheng CY; Chiu AW; Chou JC; Hsu WM; Liu JH
Ophthalmology; 2002 Dec; 109(12):2241-7. PubMed ID: 12466165
[TBL] [Abstract][Full Text] [Related]
3. Latanoprost and brimonidine: therapeutic and physiologic assessment before and after oral nonsteroidal anti-inflammatory therapy.
Sponsel WE; Paris G; Trigo Y; Pena M; Weber A; Sanford K; McKinnon S
Am J Ophthalmol; 2002 Jan; 133(1):11-8. PubMed ID: 11755835
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic success of latanoprost 0.005% compared to brimonidine 0.2% in patients with open-angle glaucoma or ocular hypertension.
Stewart WC; Day DG; Stewart JA; Holmes KT; Leech JN; Rowan CT; Schwartz GF
J Ocul Pharmacol Ther; 2000 Dec; 16(6):557-64. PubMed ID: 11132902
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the efficacy and safety of latanoprost 0.005% compared to brimonidine 0.2% or dorzolamide 2% when added to a topical beta-adrenergic blocker in patients with primary open-angle glaucoma or ocular hypertension.
Stewart WC; Sharpe ED; Day DG; Kolker AE; Konstas AG; Lee WH; Rieser JC; Chopra H; Holmes KT
J Ocul Pharmacol Ther; 2000 Jun; 16(3):251-9. PubMed ID: 10872922
[TBL] [Abstract][Full Text] [Related]
6. Initial medical management of open-angle glaucoma.
Fechtner RD
J Glaucoma; 2000 Feb; 9(1):83-6. PubMed ID: 10708236
[No Abstract] [Full Text] [Related]
7. A comparison of the efficacy and tolerability of brimonidine and latanoprost in adults with open-angle glaucoma or ocular hypertension: a three-month, multicenter, randomized, double-masked, parallel-group trial.
DuBiner HB; Mroz M; Shapiro AM; Dirks MS;
Clin Ther; 2001 Dec; 23(12):1969-83. PubMed ID: 11813932
[TBL] [Abstract][Full Text] [Related]
8. The efficacy and safety of latanoprost 0.005% once daily versus brimonidine 0.2% twice daily in open-angle glaucoma or ocular hypertension.
Stewart WC; Day DG; Stewart JA; Schuhr J; Latham KE
Am J Ophthalmol; 2001 May; 131(5):631-5. PubMed ID: 11336939
[TBL] [Abstract][Full Text] [Related]
9. Three-month comparison of brimonidine and latanoprost as adjunctive therapy in glaucoma and ocular hypertension patients uncontrolled on beta-blockers: tolerance and peak intraocular pressure lowering.
Simmons ST; Earl ML;
Ophthalmology; 2002 Feb; 109(2):307-14; discussion 314-5. PubMed ID: 11825814
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness and safety of brimonidine as adjunctive therapy for patients with elevated intraocular pressure in a large, open-label community trial.
Lee DA; Gornbein JA
J Glaucoma; 2001 Jun; 10(3):220-6. PubMed ID: 11442187
[TBL] [Abstract][Full Text] [Related]
11. A double-masked randomized crossover study comparing the effect of latanoprost/timolol and brimonidine/timolol fixed combination on intraocular pressure and ocular blood flow in patients with primary open-angle glaucoma or ocular hypertension.
Hommer A; Sperl P; Resch H; Popa-Cherecheanu A; Qiao C; Schmetterer L; Garhöfer G
J Ocul Pharmacol Ther; 2012 Dec; 28(6):569-75. PubMed ID: 22775229
[TBL] [Abstract][Full Text] [Related]
12. Brimonidine and latanoprost as adjunctive therapy.
Camras CB
Ophthalmology; 2003 Jan; 110(1):6-8; author reply 8-9. PubMed ID: 12511334
[No Abstract] [Full Text] [Related]
13. Brimonidine and latanoprost as adjunctive therapy.
Camras CB
Ophthalmology; 2004 Feb; 111(2):410-1. PubMed ID: 15019405
[No Abstract] [Full Text] [Related]
14. Washout periods for brimonidine 0.2% and latanoprost 0.005%.
Stewart WC; Holmes KT; Johnson MA
Am J Ophthalmol; 2001 Jun; 131(6):798-9. PubMed ID: 11384581
[TBL] [Abstract][Full Text] [Related]
15. Effect of 0.2% brimonidine on retinal blood flow.
Yu M; Li Y; Liu X; Ling Y; Zheng X
Yan Ke Xue Bao; 2001 Mar; 17(1):42-5. PubMed ID: 12567595
[TBL] [Abstract][Full Text] [Related]
16. The effect of brimonidine tartrate on retinal blood flow in patients with ocular hypertension.
Carlsson AM; Chauhan BC; Lee AA; LeBlanc RP
Am J Ophthalmol; 2000 Mar; 129(3):297-301. PubMed ID: 10704543
[TBL] [Abstract][Full Text] [Related]
17. The effects of latanoprost and brimonidine on blood flow velocity of the retrobulbar vessels: a 3-month clinical trial.
Inan UU; Ermis SS; Yücel A; Oztürk F
Acta Ophthalmol Scand; 2003 Apr; 81(2):155-60. PubMed ID: 12752054
[TBL] [Abstract][Full Text] [Related]
18. Comparison of brimonidine with latanoprost in the adjunctive treatment of glaucoma. ALPHAGAN/XALATAN Study Group.
Simmons ST; Samuelson TW
Clin Ther; 2000 Apr; 22(4):388-99. PubMed ID: 10823361
[TBL] [Abstract][Full Text] [Related]
19. Additive intraocular pressure lowering effect of various medications with latanoprost.
O'Connor DJ; Martone JF; Mead A
Am J Ophthalmol; 2002 Jun; 133(6):836-7. PubMed ID: 12036683
[TBL] [Abstract][Full Text] [Related]
20. The effect of latanoprost, brimonidine, and a fixed combination of timolol and dorzolamide on circadian intraocular pressure in patients with glaucoma or ocular hypertension.
Orzalesi N; Rossetti L; Bottoli A; Fumagalli E; Fogagnolo P
Arch Ophthalmol; 2003 Apr; 121(4):453-7. PubMed ID: 12695241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
